Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:OBIO OTCMKTS:POSC NASDAQ:STEX NASDAQ:TMCI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOBIOOrchestra BioMed$4.10+0.7%$4.10$2.20▼$5.42$243.71M0.5224,059 shs556,216 shsPOSCPositron$1.79-1.2%$1.84$1.27▼$2.74$59.49M0.1422,963 shs2,626 shsSTEXBiosig Technologies$0.97+2.1%$1.07$0.70▼$14.11$173.10M1.851.76 million shs1.59 million shsTMCITreace Medical Concepts$4.06+3.8%$2.42$1.17▼$7.78$253.65M1.4613,265 shs1.00 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOBIOOrchestra BioMed+1.24%+2.01%+0.25%-3.10%+28.39%POSCPositron-1.74%-3.26%-1.31%-13.67%+19.93%STEXBiosig Technologies+3.33%-19.31%+6.04%-50.92%+95,209,900.00%TMCITreace Medical Concepts-7.57%+5.96%+70.37%+167.81%-36.63%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOBIOOrchestra BioMed$4.10+0.7%$4.10$2.20▼$5.42$243.71M0.5224,059 shs556,216 shsPOSCPositron$1.79-1.2%$1.84$1.27▼$2.74$59.49M0.1422,963 shs2,626 shsSTEXBiosig Technologies$0.97+2.1%$1.07$0.70▼$14.11$173.10M1.851.76 million shs1.59 million shsTMCITreace Medical Concepts$4.06+3.8%$2.42$1.17▼$7.78$253.65M1.4613,265 shs1.00 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOBIOOrchestra BioMed+1.24%+2.01%+0.25%-3.10%+28.39%POSCPositron-1.74%-3.26%-1.31%-13.67%+19.93%STEXBiosig Technologies+3.33%-19.31%+6.04%-50.92%+95,209,900.00%TMCITreace Medical Concepts-7.57%+5.96%+70.37%+167.81%-36.63%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOBIOOrchestra BioMed 2.57Moderate Buy$13.60231.71% UpsidePOSCPositron 0.00N/AN/AN/ASTEXBiosig Technologies 2.00Hold$8.00722.88% UpsideTMCITreace Medical Concepts 1.86Reduce$4.7717.49% UpsideCurrent Analyst Ratings BreakdownLatest POSC, TMCI, OBIO, and STEX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2026STEXBiosig Technologies Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $8.005/19/2026OBIOOrchestra BioMed B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $10.005/14/2026OBIOOrchestra BioMed HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.005/13/2026OBIOOrchestra BioMed BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$12.00 ➝ $13.005/1/2026STEXBiosig Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026OBIOOrchestra BioMed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/20/2026TMCITreace Medical Concepts Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/9/2026STEXBiosig Technologies Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $9.004/2/2026OBIOOrchestra BioMed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/12/2026OBIOOrchestra BioMed Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOBIOOrchestra BioMed$33.48M7.33N/AN/A$0.95 per share4.32POSCPositron$460K127.83N/AN/A$0.04 per share44.75STEXBiosig Technologies$40K4,418.65N/AN/A$0.83 per share1.17TMCITreace Medical Concepts$212.69M1.24N/AN/A$1.37 per share2.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOBIOOrchestra BioMed-$52.70M-$0.97N/AN/AN/A-166.96%-157.46%-60.18%8/11/2026 (Estimated)POSCPositron-$10.60M-$0.33N/AN/AN/A-1,996.75%-996.81%-272.52%N/ASTEXBiosig Technologies-$462.77M-$9.71N/AN/AN/AN/A-717.92%-336.75%N/ATMCITreace Medical Concepts-$59M-$0.97N/AN/AN/A-29.44%-67.04%-30.28%8/6/2026 (Estimated)Latest POSC, TMCI, OBIO, and STEX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026POSCPositronN/A-$0.04N/A-$0.04N/A$0.11 million5/14/2026Q1 2026STEXBiosig TechnologiesN/A-$0.27N/A-$0.27N/AN/A5/12/2026Q1 2026OBIOOrchestra BioMed-$0.40-$0.33+$0.07-$0.33$0.92 million$0.11 million5/8/2026Q1 2026TMCITreace Medical Concepts-$0.31-$0.28+$0.03-$0.28$45.96 million$47.20 million3/31/2026Q4 2025POSCPositronN/A-$0.22N/A-$0.22N/A$0.11 million3/31/2026Q4 2025STEXBiosig TechnologiesN/A-$8.23N/A-$8.23N/AN/A3/12/2026Q4 2025OBIOOrchestra BioMed-$0.38$0.26+$0.64$0.26$0.93 million$30.92 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthOBIOOrchestra BioMedN/AN/AN/AN/AN/APOSCPositronN/AN/AN/AN/AN/ASTEXBiosig TechnologiesN/AN/AN/AN/AN/ATMCITreace Medical ConceptsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOBIOOrchestra BioMed0.357.037.01POSCPositronN/A0.870.59STEXBiosig TechnologiesN/A13.9013.90TMCITreace Medical Concepts0.723.582.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOBIOOrchestra BioMed53.20%POSCPositronN/ASTEXBiosig Technologies7.16%TMCITreace Medical Concepts84.08%Insider OwnershipCompanyInsider OwnershipOBIOOrchestra BioMed7.50%POSCPositron17.20%STEXBiosig Technologies52.73%TMCITreace Medical Concepts23.42%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableOBIOOrchestra BioMed459.88 million55.39 millionNot OptionablePOSCPositron2032.85 million27.20 millionNot OptionableSTEXBiosig Technologies50181.80 million85.94 millionN/ATMCITreace Medical Concepts25064.87 million49.68 millionOptionablePOSC, TMCI, OBIO, and STEX HeadlinesRecent News About These CompaniesTreace Medical Concepts (NASDAQ:TMCI) CEO John Treace Buys 22,887 SharesJune 12 at 7:18 AM | insidertrades.comTreace to Present at the Sidoti Small Cap ConferenceJune 11 at 4:05 PM | globenewswire.comTreace Medical Concepts (NASDAQ:TMCI) CEO John Treace Acquires 50,000 SharesJune 2, 2026 | insidertrades.comTreace Medical Concepts Balances Growth With Earnings StrainJune 1, 2026 | tipranks.comJohn Treace Purchases 4,508 Shares of Treace Medical Concepts (NASDAQ:TMCI) StockMay 29, 2026 | insidertrades.comWilliam Blair Investment Management LLC Sells 2,488,883 Shares of Treace Medical Concepts, Inc. $TMCIMay 27, 2026 | marketbeat.comTreace Medical Shareholders Back Directors, Pay and AuditorMay 20, 2026 | tipranks.comTreace Medical Concepts, Inc.May 15, 2026 | edition.cnn.comTreace Medical Concepts (NASDAQ:TMCI) CEO John Treace Buys 43,000 SharesMay 15, 2026 | insidertrades.comTreace Medical Concepts, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesMay 12, 2026 | globenewswire.comTreace Medical Concepts Inc (TMCI) Q1 2026 Earnings Call Highlights: Navigating Revenue ...May 9, 2026 | finance.yahoo.comTreace Medical Concepts: Q1 Earnings SnapshotMay 8, 2026 | myjournalcourier.comMTreace Medical Concepts (TMCI) Reports Q1 Loss, Beats Revenue EstimatesMay 8, 2026 | zacks.comTreace Medical Concepts Reports First Quarter 2026 Financial ResultsMay 8, 2026 | globenewswire.comTreace Medical Concepts Inc (TMCI) Q1 2026 Earnings Report Preview: What To ExpectMay 7, 2026 | finance.yahoo.comHow The Treace Medical Concepts (TMCI) Story Is Shifting With Mixed Analyst ExpectationsMay 3, 2026 | finance.yahoo.comTreace Medical Concepts, Inc. to Release First Quarter 2026 Financial Results and Host Conference CallApril 24, 2026 | quiverquant.comQTreace to Report First Quarter 2026 Financial Results on May 8, 2026April 24, 2026 | globenewswire.comHow The Treace Medical Concepts (TMCI) Narrative Is Shifting With New Targets And Product PlansApril 18, 2026 | finance.yahoo.comTreace Medical Concepts Announces Leadership Transition and OutlookApril 11, 2026 | theglobeandmail.comTreace Medical Concepts (TMCI) price target increased by 12.28% to 4.08April 10, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePOSC, TMCI, OBIO, and STEX Company DescriptionsOrchestra BioMed NASDAQ:OBIO$4.10 +0.03 (+0.74%) Closing price 04:00 PM EasternExtended Trading$4.10 0.00 (0.00%) As of 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.Positron OTCMKTS:POSC$1.79 -0.02 (-1.16%) As of 12:28 PM EasternPositron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.Biosig Technologies NASDAQ:STEX$0.97 +0.02 (+2.11%) Closing price 04:00 PM EasternExtended Trading$0.98 +0.01 (+0.80%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.Treace Medical Concepts NASDAQ:TMCI$4.06 +0.15 (+3.84%) Closing price 04:00 PM EasternExtended Trading$4.12 +0.06 (+1.35%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
